Vimpat: payments to doctors
Payments that named Vimpat as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $483K
- Providers
- 3,942
- Transactions
- 18,255
- Average per transaction
- $26
The per-transaction average — $26 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,942 providers the average total is $122, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| UCB, Inc. | $400,854 | 83.0% |
| UCB SA | $65,209 | 13.5% |
| UCB Biosciences Inc. | $11,169 | 2.3% |
| UCB GmbH | $5,596 | 1.2% |